1. P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients. (30th January 2023) Authors: Iborra Colomino, M I; Ferreiro-Iglesias, R; Martín-Arranz, M D; Mesonero-Gismero, F; Mínguez, A; Porto Silva, S; García-Ramírez, L; García de la Filia, I; Bastida, G; Nieto García, L; Suárez Ferrer, C; Aguas, M; Barreiro de Acosta, M; Nos, P Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P737 Intensification with intravenous ustekinumab in refractory Crohn′s disease. (30th January 2023) Authors: Arroyo Argüelles, J M; Suárez Ferrer, C; Rueda García, J L; Martín-Arranz, E; Poza Cordón, J; Sánchez-Azofra, M; García-Ramírez, L; Martin-Arranz, M D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i866 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗